Moreover, LAT1 has been reported to be expressed in cancer stem cells that contribute to cancer aggressiveness and resistance to therapy, and LAT1 suppression inhibits the immune checkpoint protein programmed cell death-1 ligand 1, a clinically applied target, in cancer stem cells. The gene discussed is SLC7A5; the disease is cancer.